DOI resolved by resea

Simulation of the SWTMS (Southwest Thermal Mass Study) test cells using the DOE-2. 1A model

As compared with gemcitabine, FOLFIRINOX was associated with a survival advantage and had increased toxicity. FOLFIRINOX is an option for the treatment of patients with metastatic pancreati…

H.A. McLain, J.E. Christian, S.Y. Ohr, J.L. Bledsoe
https://resea.org/10.1056/nejmoa1011923

Abstract

As compared with gemcitabine, FOLFIRINOX was associated with a survival advantage and had increased toxicity. FOLFIRINOX is an option for the treatment of patients with metastatic pancreatic cancer and good performance status. (Funded by the French government and others; ClinicalTrials.gov number, NCT00112658.).